Please select the option that best describes you:
How does genomic profiling/next-generation sequencing assays influence your treatment recommendations in metastatic breast cancer?
At what point do you send these test, and in what instances do the results influence your treatment recommendations?
Answer from: Medical Oncologist at Academic Institution
At the current time, there are no evidence-based, FDA-approved or NCCN-recommended uses of genomic or protein-based assays other than ER, PR, or HER as well as gene expression profiling results like the 21-gene/Oncotype or 70-gene MammaPrint assay for routine management of breast canc...
Sign in or Register to read more